This protocol applies to patients with pulmonary sarcoidosis who present with dyspnea, chest X-ray findings at stage II or higher, and pulmonary function tests below normal limits. This combination signals clinically significant parenchymal lung involvement warranting a structured, active treatment approach.
In patients with dyspnea, corticosteroid therapy has been shown to improve lung function — both in the short term and up to five years after therapy has been discontinued. Corticosteroids remain the initial drug of choice for treatment of parenchymal lung diseases in this setting.
The regimen for this scenario centres on oral corticosteroid therapy, initiated at a dose calibrated to the severity of presentation and then tapered progressively over several months according to a defined schedule. The full dosing plan, tapering sequence, and monitoring guidance are available in the complete protocol.
For those with dyspnea, corticosteroid therapy has been shown to improve lung function for both the short term and up to five years after therapy has been discontinued.
Corticosteroids remain the initial drug of choice for treatment of parenchymal lung diseases.
Once corticosteroids have been started, the patient is usually seen 1–3 months.
View source ↗